RNF213 Antibodies

Santa Cruz Biotechnology delivers a wide array of RNF213 monoclonal antibodies for research applications. RNF213 monoclonal antibodies are validated for western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), flow cytometry (FCM), and enzyme-linked immunosorbent assay (ELISA). RNF213, associated with the regulation of vascular development and function, plays a significant role in the pathogenesis of several vascular diseases, including moyamoya disease. Understanding RNF213's function in cellular signaling pathways and immune response mechanisms continues to advance cardiovascular and neurological research. RNF213 monoclonal antibodies enable researchers to investigate molecular pathways and disease mechanisms with precision and reliability. Studying RNF213 has led to important discoveries in vascular biology and disease progression. Current research utilizing RNF213 monoclonal antibodies contributes to developing new therapeutic strategies for vascular disorders. Santa Cruz Biotechnology monoclonal antibodies support researchers worldwide in advancing scientific understanding of RNF213's role in health and disease.